TEVA Expense Breakdown
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Quarter ended 2026-06-30 · each region line is listed as filed.
- 2026-06-30: Europe $559.00M; United States $499.00M; International Markets $266.00M.
- 2025-06-30: Europe $581.00M; United States $574.00M; International Markets $251.00M.
Expenses by region
Cost of sales: each quarter (3 month)
| Quarter end | Europe | United States | International Markets |
|---|---|---|---|
| 2026-06-30 | $559.00M | $499.00M | $266.00M |
| 2025-06-30 | $581.00M | $574.00M | $251.00M |
General and Administrative Expense: each quarter (3 month)
| Quarter end | Europe | United States | International Markets |
|---|---|---|---|
| 2026-06-30 | $66.00M | $107.00M | $38.00M |
| 2025-06-30 | $66.00M | $111.00M | $32.00M |
Research and Development Expense (Excluding Acquired in Process Cost): each quarter (3 month)
| Quarter end | Europe | United States | International Markets |
|---|---|---|---|
| 2026-06-30 | $52.00M | $883.00M | $26.00M |
| 2025-06-30 | $59.00M | $152.00M | $24.00M |
Selling and Marketing Expense: each quarter (3 month)
| Quarter end | Europe | United States | International Markets |
|---|---|---|---|
| 2026-06-30 | $222.00M | $294.00M | $128.00M |
| 2025-06-30 | $228.00M | $250.00M | $114.00M |